Compare F.N.B. Corporation Common Stock (FNB) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F.N.B. Corporation Common Stock vs DENTSPLY SIRONA Inc — how do they compare? F.N.B. Corporation Common Stock trades at $16.91 (market cap $6.07B), while DENTSPLY SIRONA Inc trades at $8.54 (market cap $1.70B). The key difference: F.N.B. Corporation Common Stock is far larger — about 3.6× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals — on Pluang, investors hold F.N.B. Corporation Common Stock for 0 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| FNB | XRAY | |
|---|---|---|
Market Cap | $6.07B | $1.70B |
Volume | 5,600,609 | 3,939,845 |
Sector | Financials | Health |
52-Week High | $19.49 | $14.68 |
52-Week Low | $14.65 | $8.44 |
Typical Hold Time | 0 Days | 72 Days |
Enterprise Value | $10.61B | $3.77B |
Dividend Yield | 3.05% | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNB trades at $17.05, down 0.76% on the day, with a neutral technical signal. The stock shows solid fundamentals with a P/E of 10.15 and P/B of 0.89, indicating potential undervaluation. Recent earnings have been mixed, with Q2 2026 beating estimates but Q1 missing. Revenue remains stable at $1.77 billion for 2025, with a strong net income margin of 33.04%. Analyst sentiment is positive, with 13 buy ratings and a consensus price target of $20.80.
The outlook for FNB is cautiously optimistic, supported by strong profitability and a favorable analyst consensus. Key opportunities include potential upside to the price target and consistent dividend payments. Risks involve earnings volatility, as seen in recent quarters, and competitive pressures in the banking sector. Investors should weigh the attractive valuation against execution risks and market conditions.
XRAY trades at $8.44, down 1.06% on the day and near its 52-week low, reflecting persistent bearish technical signals. The company reported a net loss of $598 million in 2025, with negative profit margins and declining revenue, though Q2 2026 earnings beat expectations. Debt-to-asset ratio has risen to 42.88% in 2025, indicating increased financial leverage amid ongoing restructuring efforts.
The outlook remains challenging with weak profitability and high debt, but analyst consensus suggests potential upside to a $13.00 price target. Key risks include margin pressure, competitive threats, and execution of the turnaround plan. Investment appeal hinges on successful operational improvements and sustained earnings recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About F.N.B. Corporation Common Stock
F.N.B. Corporation is a diversified financial services holding company headquartered in Pittsburgh, Pennsylvania, operating through its lead subsidiary, First National Bank of Pennsylvania. It provides commercial banking, consumer banking, wealth management, and insurance through more than 350 banking offices across seven states and Washington, D.C.
Read more on FNB →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
